Diagnostics Market – Sector Evolution

The Indian diagnostics sector stands at a structural inflection point, where the convergence of deep-tech integration, a shift toward consumer-centric wellness, and vast untapped market potential is unlocking a multi-decade growth runway that is still in its nascent stages. Indian diagnostics sector itself is projecting ₹120,000cr. market by FY28E, increasing at 8-10% CAGR, with the mix of 60% pathology and 40% radiology.

Today, only 17% of diagnostic service providers are from the organized sector, 37% are hospital-based labs and a whopping 46% are from the unorganized standalone labs. The organized segment brings a new paradigm – one defined by standardization, adherence to stringent quality protocols, and the integration of advanced diagnostic technologies. Even more surprising is that in India, only 3%, labs are NABL accredited, and reporting accuracy is a major concern. This is the scenario, even though about 70% of treatment decisions are based on diagnostics tests. Therefore, focusing on this transition towards organizing the sector is a need of the hour.

During the periods of onslaught of COVID, the wave of diagnostics first startups pushed the industry towards to its "Startup-ification" process which has led it to a "Price-Value Paradox”: while tests have become cheaper and more accessible, the quality of reporting, ease of booking, and focus on longevity have significantly improved. New age startups have also fuelled the structural shift from unorganized to organized, consolidating the industry from ~10-15% organized to ~22%+ post covid. They have forced the incumbent players to become more agile in:

• Operations - launch of home collection and mobile apps with reduced TATs

• Marketing philosophy from just being B2B i.e. doctor led to B2C-B2B led, allowing customer to choose

• Tests – Dynamic pricing with options of niche e.g. wellness, GLP-1, etc testing.

Diagnostics has been a high-margin, low-capex, low-working-capital business with strong RoCE and robust cash generation.

Looking at the market capitalization journey of the listed diagnostics players between FY17 and TTM; it expanded from ~₹11,929cr (with only two listed names — Dr. Lal PathLabs and Thyrocare Technologies) to ~₹55,129cr, with six independently listed players today. Pre-COVID, diagnostics was a relatively under-recognised segment within healthcare. The pandemic marked a structural inflection — between FY20 and FY22, sector market cap surged ~2.5x as COVID testing volumes, heightened healthcare awareness, and a wave of new listings brought the sector into institutional focus as a critical value driver in the medical ecosystem.

Post-COVID (FY22 to TTM), despite normalization of testing revenues, aggregate sector market cap has largely reverted to its COVID-peak levels. However, PAT across players has grown ~19% over the same period. This divergence underscores two key themes: (1) earnings sustainability beyond pandemic windfalls, and (2) a sector that has structurally expanded in scale and profitability even as valuations have moderated. In effect, the industry appears to have retained its enlarged earnings base while shedding the excess froth of COVID-era multiples.

Prior to 2015, the diagnostic sector was largely unorganized and regional, but the listings of Dr. Lal PathLabs in 2015 and Thyrocare in 2016 introduced immediate high P/E multiples. Investors categorized diagnostics as "FMCG-plus," attracted by a business model featuring high EBITDA margins of 25-30%, negative working capital, and low maintenance capex; this limited number of listed entities allowed them to enjoy a significant "scarcity premium."

The steep dip in FY18-19 was driven by a sudden surge in competitive intensity. Regional players and large hospital chains aggressively expanded their retail diagnostic footprints. Simultaneously, the market began to price in regulatory overhangs (fears of government price caps on essential tests) and pricing headwinds in routine pathology, stripping away the initial scarcity premium.

The pandemic later fundamentally re-rated the sector as diagnostics evolved from a medical necessity into a daily utility for the Indian population. Massive cash flows from COVID-19 testing were viewed as growth capital for acquiring smaller labs, as investors priced in permanent shifts in health-consciousness.

As COVID-19 revenues vanished, the sector faced a "margin reset." Digital aggregators (like Tata 1mg and PharmEasy) disrupted the market by offering routine wellness packages at massive discounts, commoditizing basic tests.

Currently, the valuation landscape is no longer "one-size-fits-all." The market has transitioned from rewarding purely volume-led growth (opening new collection centers for routine tests) to rewarding mix-led growth. Today's multiple reflects a highly discriminatory market that pays a premium only for players successfully migrating toward high-margin specialized testing (genomics, molecular) and integrated Radiology-Pathology models.

To better contextualize valuation multiples, it is essential to first examine the underlying business model of diagnostics players. Margin profile, capital intensity, and working capital dynamics vary meaningfully depending on the radiology–pathology mix and the operating model (B2C, B2B, integrated, or PPP). These structural differences can ultimately drive growth quality, RoCE sustainability, and earnings visibility.

Now, in order to capture the mix of the above two mentioned industry offerings the industry has evolved into the following business practices:

1. B2C Pathology-Centric Model (Direct-to-Consumer)

• Strategic Value Drivers: These players leverage high brand equity and "neighbourhood" presence to build direct patient relationships. Success is driven by network density (collection centers) and a shift from sick-care to preventive wellness packages, which are less price-sensitive.

• Financial Profile:

  • Margins: Enjoy the high Gross Margins (~70-75%) and EBITDA margins (~25-30%) due to the absence of institutional middlemen.

  • Revenue Metrics: Characterized by high Realization Per Patient than B2B as they can upsell comprehensive health bundles.

  • Capital Efficiency: Operates on an "Asset-Light" spoke-and-hub model; low working capital requirements as most transactions are cash-and-carry. This supports a structurally superior RoCE.

2. B2B Pathology-Centric Model (Institutional/Lab-to-Lab)

• Strategic Value Drivers: This model functions as a high-volume processing engine for smaller labs, nursing homes, and clinics. Growth is strictly volume-led, requiring massive scale and logistical precision to maintain a competitive Cost Per Test.

• Financial Profile:

  • Margins: Thinner Gross Margins compared to B2C peers, as pricing power stays with the referring institution.

  • Working Capital: Higher Days Sales Outstanding (DSO) because of credit periods extended to institutional clients.

  • Operational Moat: While margins are lower, the high Asset Turnover (utilizing central lab machines 24/7) ensures healthy RoCE once a certain volume threshold is breached.

3. Integrated B2C Radiology & Imaging Model

• Strategic Value Drivers: High entry barriers due to heavy CAPEX (MRI, CT, PET-CT) and the requirement for specialized on-site radiologists. These players often adopt an "Integrated Model" (combining Pathology + Radiology), which acts as a "one-stop-shop" for clinicians, increasing patient stickiness.

• Financial Profile:

  • Margins: Superior EBITDA margins due to the high-value nature of advanced imaging; however, these are partially offset by high maintenance contracts and power costs.

  • Capital Intensity: High upfront investment leads to lower initial ROCE compared to pathology-only players. However, they enjoy high Operating Leverage—once the "break-even" number of scans is met, incremental revenue flows directly to the bottom line.

  • Moat: Protected from digital aggregators, as radiology requires the physical presence of the patient and specialized infrastructure.

4. Public-Private Partnership (PPP) & Government-Linked Models

• Strategic Value Drivers: These entities focus on "Universal Access," operating within government hospitals or standalone centers under state contracts. They compete primarily on disruptive pricing, offering essential tests at a 50–70% discount compared to the private retail market.

• Financial Profile:

  • Structural Advantages: Benefit from zero-to-subsidized rentals, no marketing/doctor referral costs, and lower utility overheads.

  • Risk Profile: Faces significant Working Capital pressure due to chronic delays in government reimbursements.

  • Commercial Discipline: Generally characterized by lower administrative agility and a heavy reliance on high-volume government mandates to offset the thin per-test realizations.

With the core business models mapped, the next question is what could structurally expand the addressable market and shift the diagnostic mix over the next cycle.

• One of the fast-evolving segments for diagnostics is of GLP-1 therapies. There remains a huge opportunity for long term growth for therapy specific tests, tied to doctor/patient adoption. Players like Thyrocare and Metropolis are actively pursuing this opportunity with their GLP-1 packages. The initial uptake has been slow just cause the Indian GLP-1 market is still in its infancy with growth projected to see an uptick soon i.e. March’26 when the innovators go off patent.

• Another, key arena of growth arises from the genomics testing market is expected to grow at a 15% CAGR over the next five years, driven by rising demand for personalized medicine. By analysing individual genetic profiles, providers can design more targeted treatment plans and better predict inherited disease risks — shifting healthcare from reactive to proactive. In India specifically, this translates to a market opportunity of ~$200M by FY27.

Risks for the industry

• The Aggregator Threat: Digital platforms like Tata 1mg and PharmEasy (Thyrocare) have commoditized routine tests (CBC, Lipid Profile). Their low-margin, high-volume model forces listed leaders to either cut prices or lose the "routine" market.

• Hospital Expansion: Large hospital chains (Apollo, Max, Fortis/Agilus) are aggressively building retail diagnostic wings. Since they already own the patient "entry point," they can divert high-value specialized tests away from standalone labs.

• Import Costs: The industry faces a structural reliance on imports, with 60–70% of reagents and equipment sourced globally. While INR depreciation typically impacts EBITDA margins by 20–50 bps, the Union Budget 2026 has introduced immediate cost headwinds:

  • Effective Feb 2, 2026: Withdrawal of customs exemptions on diagnostic/lab reagents and artificial plasma.

  • Effective April 1, 2026: Withdrawal of exemptions for critical X-ray components (tubes and flat-panel detectors).

  • Strategic Impact: These policy shifts signal a clear government push toward domestic manufacturing. In the short term, however, this will likely lead to higher CAPEX and OPEX for listed players until local supply chains mature.